{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:33:41Z","timestamp":1787758421375,"version":"build-2784847793"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.4103\/jispcd.jispcd_110_22","type":"journal-article","created":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T10:11:32Z","timestamp":1667124692000},"page":"564-570","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Contribution of Antiangiogenic Agents to the Risk of Medication-related Osteonecrosis of the Jaw in Combination with Antiresorptive Agents"],"prefix":"10.4103","volume":"12","author":[{"given":"Antoine","family":"Yanni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Bouland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Loeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rokneddine","family":"Javadian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Dequanter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20240828","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (aredia) and zoledronate (zometa) induced avascular necrosis of the jaws: A growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"R2-11-20240828","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"R3-11-20240828","first-page":"CD008455","article-title":"Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ)","volume":"2","author":"Rollason","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R4-11-20240828","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jormas.2020.05.024","article-title":"Case reports of medication-related osteonecrosis of the jaw (MRONJ) treated with uncultured stromal vascular fraction and L-PRF","volume":"122","author":"Bouland","year":"2021","journal-title":"J Stomatol Oral Maxillofac Surg"},{"key":"R5-11-20240828","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.surge.2011.09.002","article-title":"Bisphosphonate osteonecrosis of the jaw: A historical and contemporary review","volume":"10","author":"McLeod","year":"2012","journal-title":"Surgeon"},{"key":"R6-11-20240828","doi-asserted-by":"crossref","first-page":"8345309","DOI":"10.1155\/2019\/8345309","article-title":"Medication-related osteonecrosis of the jaws: Two center retrospective cohort studies","volume":"2019","author":"Petrovic","year":"2019","journal-title":"Biomed Res Int"},{"key":"R7-11-20240828","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.4317\/medoral.23191","article-title":"Review and update on drugs related to the development of osteonecrosis of the jaw","volume":"25","author":"Eguia","year":"2020","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"R8-11-20240828","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"key":"R9-11-20240828","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.job.2019.03.005","article-title":"Medication-related osteonecrosis of the jaw: A literature review","volume":"61","author":"Kuroshima","year":"2019","journal-title":"J Oral Biosci"},{"key":"R10-11-20240828","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/07357900802208608","article-title":"Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents","volume":"27","author":"Aragon-Ching","year":"2009","journal-title":"Cancer Invest"},{"key":"R11-11-20240828","doi-asserted-by":"crossref","first-page":"8071579","DOI":"10.1155\/2018\/8071579","article-title":"Osteonecrosis of the jaw associated with antiangiogenics in antiresorptive-naive patient: A comprehensive review of the literature","volume":"2018","author":"Pimolbutr","year":"2018","journal-title":"Biomed Res Int"},{"key":"R12-11-20240828","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"R13-11-20240828","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"26","author":"Estilo","year":"2008","journal-title":"J Clin Oncol"},{"key":"R14-11-20240828","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1620\/tjem.248.27","article-title":"Antiresorptive agents and anti-angiogenesis drugs in the development of osteonecrosis of the jaw","volume":"248","author":"Allegra","year":"2019","journal-title":"Tohoku J Exp Med"},{"key":"R15-11-20240828","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bone.2013.10.002","article-title":"Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients","volume":"58","author":"Lescaille","year":"2014","journal-title":"Bone"},{"key":"R16-11-20240828","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.joms.2021.05.014","article-title":"Medication-related osteonecrosis of the jaw","volume":"79","author":"Ferneimi","year":"2021","journal-title":"J Oral Maxillofac Surg"},{"key":"R17-11-20240828","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00198-015-3335-3","article-title":"Osteonecrosis of the jaw (ONJ): Diagnosis and management in 2015","volume":"27","author":"Khan","year":"2016","journal-title":"Osteoporos Int"},{"key":"R18-11-20240828","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1749-6632.2010.05768.x","article-title":"Bisphosphonate-related osteonecrosis of the jaw: An overview","volume":"1218","author":"Ruggiero","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"R19-11-20240828","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omsc.2017.03.001","article-title":"Osteonecrosis of jaw after antiangiogenic agent administration in a renal cell carcinoma patient","volume":"3","author":"Jung","year":"2017","journal-title":"Oral Maxillofac Surg Cases"},{"key":"R20-11-20240828","doi-asserted-by":"crossref","first-page":"15593258221093410","DOI":"10.1177\/15593258221093410","article-title":"Investigation of the antiangiogenic properties of zoledronic acid by using chorioallantoic membrane model","volume":"20","author":"Gulcu","year":"2022","journal-title":"Dose Response"},{"key":"R21-11-20240828","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons\u2019 position paper on medication-related osteonecrosis of the jaws\u20142022 update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J Oral Maxillofac Surg"},{"key":"R22-11-20240828","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4317\/medoral.24197","article-title":"Proposal for a preventive protocol for medication-related osteonecrosis of the jaw","volume":"26","author":"Romero-Ruiz","year":"2021","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"R23-11-20240828","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00106-021-01130-0","article-title":"[Management of medication-related osteonecrosis of the jaw\u2014A review of recent study results in comparison to established strategies]","volume":"70","author":"Tr\u00f6ltzsch","year":"2022","journal-title":"HNO"},{"key":"R24-11-20240828","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/j.bjoms.2021.03.006","article-title":"Systematic review of medication related osteonecrosis of the jaw (MRONJ) in patients undergoing only antiangiogenic drug therapy: Surgery or conservative therapy?","volume":"60","author":"Sacco","year":"2022","journal-title":"Br J Oral Maxillofac Surg"}],"container-title":["Journal of International Society of Preventive and Community Dentistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jispcd.JISPCD_110_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:12:37Z","timestamp":1787757157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jispcd.JISPCD_110_22"}},"subtitle":["Preliminary Results in a Comparative Prospective Report of 59 Oncologic Cases"],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jispcd.jispcd_110_22","relation":{},"ISSN":["2231-0762"],"issn-type":[{"value":"2231-0762","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}